- This event has passed.
Premier Event: The Impact of Pharmaceutical Innovation on Premature Mortality and Hospitalisation in Australia, a Fireside Chat with Professor Lichtenberg
October 16, 2019 @ 5:00 pm - 7:00 pm AEDT
Event Navigation
BioMelbourne Network in Collaboration with Medicines Australia presents a Fireside Chat:
Helping Australians to live longer and better – at what cost? The Impact of Pharmaceutical Innovation on Premature Mortality
with leading global health economist Professor Frank Lichtenberg and Chair, Medicines Australia, Dr Anna Lavelle and facilitated by Paul Cross, Founder and Publisher of the Daily Dispatch
BioMelbourne Network and Medicines Australia, supported by Janssen, Bristol-Myers Squibb, Roche, Sanofi, MSD and GSK, are pleased to be holding an exclusive Fireside Chat and we encourage you to join the conversation.
This premier event will feature a keynote address from Professor Frank Lichtenberg – the Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business (bio below). Professor Lichtenberg will present his findings on the impact of pharmaceutical innovation on premature mortality and hospitalisation in Australia, 1998-2018.
This will be followed by an in depth interview facilitated by Paul Cross, Founder and Publisher of the Daily Dispatch with both Professor Lichtenberg and Dr Anna Lavelle to explore the impact of this innovation on mortality, quality of life, hospital utilisation and the costs implications of that.
Professor Lichtenberg’s compelling analysis highlights that pharmaceutical innovation is responsible for almost all of the decline in premature mortality between 1998 and 2015 and about half of the increase in the mean age at death from cancer between 2008 and 2018.
Outcomes from Professor Lichtenberg’s research continues the discussion about the environment for new medicines in Australia. A sophisticated health evaluation system will lead to better, more transparent policy decisions, and would demonstrate the true net cost/value of the Pharmaceutical Benefits System.
Welcome address given by Dr Anna Lavelle, Chair, Medicines Australia
Hosted by:
When: Wednesday, 16th October, 2019
Time: 5pm to 7pm – Presentation and Fireside Chat followed by networking (Registration from 4:45pm)
Where: KPMG, Level 36, Tower 2, 727 Collins Street, Melbourne VIC 3000 Australia
Bookings: Members $75 (inc. GST), Non Members $170 (inc. GST)
Check if your organisation is a member
Cancellation policy:
A full refund is given up to 7 days prior to the event. No refunds within 7 days of the event.
Click for Speaker Bios:
Professor Frank Lichtenberg, Courtney C. Brown Professor of Business Economics & Courtney C. Brown Professor of Business Healthcare and Pharmaceutical Management Program
Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research! America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations. He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an affiliate of the economics consulting firm Analysis Group.
Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research! America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations. He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an affiliate of the economics consulting firm Analysis Group.
Paul Cross, Founder and Publisher, DailyDispatch
Paul Cross is the founder of DailyDispatch, the publisher of PharmaDispatch,BiotechDispatch and HealthDispatch, online journals focused on providing news and analysis concerning the Australian pharmaceutical, biotechnology and private health sectors. He has over 15 years experience in health care, having served in senior roles in government and the private sector.
Dr Anna Lavelle PhD, FTSE, GAICD, Chair, Medicines Australia
Dr Anna Lavelle was appointed as Chair of the Medicines Australia Board in August 2018.
Prior to this Dr Lavelle served as Deputy Chair and Independent Director of Medicines Australia from January 2017 to July 2018. Dr Lavelle is an experienced non – executive director serving for over 25 years on the boards of not for profit, government and for profit entities. As executive director or non-executive director she has a lengthy track record in healthcare delivery, technology development and negotiating government policy.
From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including, Chair Australia National Digital Health initiative (ANDHealth), Independent Director SoilCRC, Chair Avatar Broking, Member Health Innovation Advisory Committee (National Health & Medical Research Council), non-executive director Hemideina and Advisor to MTPConnect.
Prior to this Dr Lavelle served as Deputy Chair and Independent Director of Medicines Australia from January 2017 to July 2018. Dr Lavelle is an experienced non – executive director serving for over 25 years on the boards of not for profit, government and for profit entities. As executive director or non-executive director she has a lengthy track record in healthcare delivery, technology development and negotiating government policy.
From 2005 to 2016, Dr Lavelle was the CEO of AusBiotech; the national industry association for the biotechnology, pharmaceutical and medical devices sectors. Dr Lavelle is now serving on several boards including, Chair Australia National Digital Health initiative (ANDHealth), Independent Director SoilCRC, Chair Avatar Broking, Member Health Innovation Advisory Committee (National Health & Medical Research Council), non-executive director Hemideina and Advisor to MTPConnect.
